NYSE:MRK 20 May 2026

Finance·Health·NASDAQ:BGNE·NASDAQ:JAZZ·NASDAQ:ONC·News·NYSE:MRK·Stock Market

BeOne Dips on Wall Street After Cancer Results, Market Looks On

BeOne Medicines shares fell 2.7% to $291.98 Thursday afternoon despite positive late-stage cancer trial data, while the Nasdaq Biotechnology Index rose 1.1%. The Phase 3 HERIZON-GEA-01 trial showed BeOne’s ZIIHERA combo reached median overall survival of 26.4 months versus 19.2 months for the control. Investors appeared cautious ahead of more data expected at the ASCO meeting next week.

May 28, 2026

Finance·Health·NASDAQ:EXEL·News·NYSE:MRK·Stock Market

Exelixis Up After Merck Pact Focuses Attention on Cancer Study

Exelixis shares rose 2.5% to $49.89 Wednesday after announcing Merck will supply Keytruda Qlex for its planned phase 3 STELLAR-316 colorectal cancer trial. The company also highlighted a $750 million buyback and a December 3 FDA decision date for zanzalintinib. Exelixis’ market value reached about $13.3 billion.

May 20, 2026

XRO and WTC Shares: Key ASX Stock Insights and Performance Analysis
May 28, 2026, 4:40 PM EDT. Xero Ltd (ASX:XRO) and WiseTech Global Ltd (ASX:WTC) are notable Australian Securities Exchange stocks to watch. Since 2025, XRO shares have fallen 33.6%, while WTC shares are 70% below their 52-week high. Xero, a cloud-based accounting software leader, grew revenues by 26.4% annually to $1.7 billion in FY24 with a net profit rise from -$9 million to $175 million and a 14.3% return on equity (ROE). WiseTech, specializing in logistics software, reported revenue growth of 27.1% yearly to $1.04 billion with net profit up from $108 million to $263 million and a 12.8% ROE. These fundamentals reflect significant growth but require further valuation context for investing decisions.